Caspofungin Inhalation Composition with PVP Stabilizer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary infections caused by Aspergillus species, particularly in immunocompromised patients, rely on systemic administration of antifungal agents, which are associated with significant side effects and instability issues with caspofungin, a key antifungal drug, due to its degradation at room temperature.
Innovation Solution
Development of a composition for inhalation administration comprising caspofungin and polyvinylpyrrolidone (PVP), which is stable and provides a high concentration of caspofungin in lung tissue, minimizing systemic exposure and extending its presence above the minimum inhibitory concentration for an extended period.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If caspofungin is administered intravenously or orally, then systemic antifungal coverage is achieved, but significant side effects and systemic toxicity occur
Solution Approach 1:
The patent applies local quality by formulating caspofungin for inhalation administration to achieve high drug concentration specifically in the lung tissue where Aspergillus infection occurs, while minimizing systemic exposure. The composition delivers caspofungin directly to the site of infection through aerosolized particles, creating a localized therapeutic effect that spares the rest of the body from toxic effects
Solution Approach 2:
The patent uses polyvinylpyrrolidone (PVP) as an intermediary excipient that stabilizes caspofungin and enables its delivery via inhalation. PVP forms a stable complex with caspofungin that protects the drug from degradation during aerosolization and storage, while also facilitating pulmonary delivery and retention of the drug at the infection site
2Ease of operation
If caspofungin is stored at room temperature, then ease of storage is improved, but drug stability deteriorates due to degradation
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical environment of caspofungin through formulation with PVP and adjustment of pH to between 3 and 7. This formulation approach changes the stability parameters of caspofungin, allowing it to remain stable at room temperature rather than requiring refrigeration, thereby improving storage convenience while maintaining drug integrity
Solution Approach 2:
PVP serves as a stabilizing intermediary that protects caspofungin from degradation at room temperature. The polymer forms a protective complex with the drug molecule, preventing hydrolysis and other degradation pathways that would otherwise occur under ambient storage conditions
3Stability of the object's composition
If inhalation composition is formulated with stabilizing excipients, then drug stability is improved, but composition complexity increases
Solution Approach 1:
The patent applies composite materials by formulating caspofungin with PVP to create a stable inhalation composition. This composite formulation combines the antifungal drug with a biocompatible polymer excipient that provides stabilization during storage and aerosolization, achieving enhanced stability while maintaining relatively simple composition and manufacturing processes
Data Source
AI summary
Compositions and corresponding methods for the treatment and/or prevention of a fungal infection in the pulmonary system of a subject in need thereof with caspofungin or a derivative thereof are disclosed herein.